(Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12th focused on testis cancer. In this session, the organizers convened a “Clinical Trials Corner” in which Dr. Darren Feldman presented an update on the TIGER trial (Alliance A021102 and EORTC E1407), a randomized phase III trial of TIP vs TI-CE as initial salvage chemotherapy for patients with germ cell tumors (GCT).